PCL Inc is a Korea-based company principally engaged in development and manufacture of vitro diagnostic medical device for immunological diagnosis. The Companyâ€™s products include blood bank screening products and quick diagnostic products. And the Company also provides platform services.

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

End-of-day quote Korea S.E. Other stock markets 21/03/2025			5-day change	1st Jan Change
6,040.00 ^KRW	-1.63%		-.--%	-

30/24/30	Yeom Ju-hwan agreed to acquire 36.90% stake in mCureX Therapeutics, Inc. from PCL, Inc. for KRW 13.0 billion.	CI
30/24/30	PCL, Inc. announced that it has received KRW 4.004999835 billion in funding	CI

Market Cap	1.68TCr 1.11Cr 95.73L 88.01L 82.84L 1.56Cr 104.72Cr 1.57Cr 10Cr 4.06Cr 51Cr 4.16Cr 4.08Cr 177.8Cr	P/E 2023	-7.17x	P/E 2024	-0.59x
Enterprise Value	2.38TCr 1.57Cr 1.36Cr 1.25Cr 1.17Cr 2.21Cr 148.53Cr 2.23Cr 15Cr 5.76Cr 73Cr 5.91Cr 5.78Cr 252.18Cr	EV / Sales 2023	22.8x	EV / Sales 2024	31.9x
Free-Float	98.99%	Yield 2023 *	-	Yield 2024	-

30/24/30	Yeom Ju-hwan agreed to acquire 36.90% stake in mCureX Therapeutics, Inc. from PCL, Inc. for KRW 13.0 billion.	CI
30/24/30	PCL, Inc. announced that it has received KRW 4.004999835 billion in funding	CI
22/24/22	PCL, Inc. announced that it expects to receive KRW 4.004999835 billion in funding	CI
25/24/25	PCL, Inc. announced that it has received KRW 9.99999838 billion in funding from JS & Partners Co., Ltd.	CI
21/24/21	Tiger Company Ltd. announced that it has received KRW 8.3 billion in funding from PCL, Inc.	CI
16/24/16	PCL, Inc. announced that it has received KRW 9.99999885 billion in funding from Global Emerging Markets	CI
26/23/26	PCL, Inc. announced that it has received KRW 9.99999838 billion in funding from Global Emerging Markets	CI
21/23/21	PCL, Inc. announced that it expects to receive KRW 9.99999885 billion in funding from Global Emerging Markets	CI
15/23/15	PCL, Inc. announced that it expects to receive KRW 9.99999838 billion in funding from JS & Partners Co., Ltd.	CI
31/23/31	South Korean Stocks Close Lower as Uncertainties Around US Debt Ceiling Deal Remain; PCL Loses 13%	MT
31/23/31	PCL to Raise 36 Billion Won via Share Issuance	MT
23/23/23	PCL, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
29/22/29	PCL, Inc. announced that it has received KRW 2.999990812 billion in funding from Hyeopsim Co ., Ltd.	CI

3 years	5,900	94,500
5 years	5,900	4,30,000
10 years	5,900	5,23,333.33

PCL, Inc. Share Price

Stocks

A241820

KR7241820000

Biotechnology & Medical Research

Valuation: PCL, Inc.

Latest news : PCL, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: PCL, Inc.

Bio Diagnostics & Testing

Financials

Company Profile

Income Statement and Estimates

Manager	Title	Age	Since
So-Yeon Kim CEO	Chief Executive Officer	55	-
Seong-Woo Lee SAM	Sales & Marketing	42	28/03/2024
Mu-Yong So AUD	Comptroller/Controller/Auditor	53	28/03/2024

Director	Title	Age	Since
So-Yeon Kim BRD	Director/Board Member	55	-
Chul-Joon Kim BRD	Director/Board Member	73	-
Mu-Yong So BRD	Director/Board Member	53	28/03/2024

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PCL, INC.	-1.63%	-.--%	-.--%	-88.17%	1.11Cr
VERACYTE, INC.	+0.73%	+6.48%	+91.67%	+96.59%	409.26Cr
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-2.56%	-1.70%	+65.48%	+100.00%	268.55Cr
BGI GENOMICS CO., LTD.	+0.56%	+1.30%	-31.97%	-41.39%	194.14Cr
IOVANCE BIOTHERAPEUTICS, INC.	+2.88%	+3.97%	+94.55%	-51.60%	175.48Cr
CAREDX, INC.	+0.99%	+0.09%	+20.29%	+194.97%	121.3Cr
SEEGENE, INC.	+3.51%	+6.31%	-11.81%	+23.69%	90Cr
MARAVAI LIFESCIENCES HOLDINGS, INC.	+4.19%	+2.76%	+149.76%	-62.12%	77Cr
CURIOX BIOSYSTEMS CO., LTD	+5.97%	-5.06%	+68.25%	-	75Cr
HANGZHOU ALLTEST BIOTECH CO., LTD.	-2.50%	-6.67%	-30.65%	-17.20%	52Cr
Average	+1.21%	+0.79%	+41.56%	+17.20%	146.3Cr
Weighted average by Cap.	+0.89%	+2.55%	+56.00%	+49.91%

	2023	2024
Net sales	842.95Cr 55.66L 48.02L 44.15L 41.56L 78.09L 53Cr 78.74L 5.23Cr 2.04Cr 26Cr 2.09Cr 2.04Cr 89Cr	124.62Cr 8L 7L 7L 6L 11.54L 7.77Cr 11.64L 77.35L 30.11L 3.81Cr 30.89L 30.23L 13Cr
Net income	-2.03TCr -1.34Cr -1.16Cr -1.06Cr -1Cr -1.88Cr -126.62Cr -1.9Cr -13Cr -4.91Cr -62Cr -5.04Cr -4.93Cr -214.98Cr	-5.23TCr -3.46Cr -2.98Cr -2.74Cr -2.58Cr -4.85Cr -326.17Cr -4.89Cr -32Cr -13Cr -160.08Cr -13Cr -13Cr -553.78Cr
Net Debt	720.41Cr 47.57L 41.04L 37.73L 35.51L 66.73L 45Cr 67.29L 4.47Cr 1.74Cr 22Cr 1.79Cr 1.75Cr 76Cr	703.02Cr 46.42L 40.05L 36.82L 34.66L 65.12L 44Cr 65.67L 4.36Cr 1.7Cr 22Cr 1.74Cr 1.71Cr 74Cr